Defining the inflammatory signature of human lung explant tissue in the presence and absence of glucocorticoid [version 1; referees: 2 approved]

Background: Airway inflammation is a feature of many respiratory diseases and there is a need for newer, more effective anti-inflammatory compounds. The aim of this study was to develop an ex vivo human lung explant model which can be used to help study the mechanisms underlying inflammatory respons...

Full description

Bibliographic Details
Main Authors: Tracy L Rimington, Emily Hodge, Charlotte K Billington, Sangita Bhaker, Binaya K C, Iain Kilty, Scott Jelinsky, Ian P Hall, Ian Sayers
Format: Article
Language:English
Published: F1000 Research Ltd 2017-04-01
Series:F1000Research
Subjects:
Online Access:https://f1000research.com/articles/6-460/v1
id doaj-2beaa65a72814bba8b062eba6979408a
record_format Article
spelling doaj-2beaa65a72814bba8b062eba6979408a2020-11-25T03:10:47ZengF1000 Research LtdF1000Research2046-14022017-04-01610.12688/f1000research.10961.111814Defining the inflammatory signature of human lung explant tissue in the presence and absence of glucocorticoid [version 1; referees: 2 approved]Tracy L Rimington0Emily Hodge1Charlotte K Billington2Sangita Bhaker3Binaya K C4Iain Kilty5Scott Jelinsky6Ian P Hall7Ian Sayers8Division of Respiratory Medicine, University of Nottingham, Nottingham, UKDivision of Respiratory Medicine, University of Nottingham, Nottingham, UKDivision of Respiratory Medicine, University of Nottingham, Nottingham, UKDivision of Respiratory Medicine, University of Nottingham, Nottingham, UKDepartment of Mechanical Engineering, Kathmandu University, Dhulikhel, NepalInflammation & Remodelling Research Unit, Pfizer Inc, Cambridge, MA, USAInflammation & Remodelling Research Unit, Pfizer Inc, Cambridge, MA, USADivision of Respiratory Medicine, University of Nottingham, Nottingham, UKDivision of Respiratory Medicine, University of Nottingham, Nottingham, UKBackground: Airway inflammation is a feature of many respiratory diseases and there is a need for newer, more effective anti-inflammatory compounds. The aim of this study was to develop an ex vivo human lung explant model which can be used to help study the mechanisms underlying inflammatory responses and which can provide a tool to aid drug discovery for inflammatory respiratory diseases such as asthma and COPD. Method: Parenchymal lung tissue from 6 individual donors was dissected and cultured with two pro-inflammatory stimuli, lipopolysaccharide (LPS) (1 µg/ml) and interleukin-1 beta (IL-1β) (10 ng/ml) in the presence or absence of dexamethasone (1 µM).  Inflammatory responses were assessed using Luminex analysis of tissue culture supernatants to measure levels of 21 chemokines, growth factors and cytokines. Results: A robust and reproducible inflammatory signal was detected across all donors for 12 of the analytes measured following LPS stimulation with a modest fold increase (<2-fold) in levels of CCL22, IL-4, and IL-2; increases of 2-4-fold in levels of CXCL8, VEGF and IL-6 and increases >4-fold in CCL3, CCL4, GM-CSF, IL-10, TNF-α and IL-1β.  The inflammatory signal induced by IL-1β stimulation was less than that observed with LPS but resulted in elevated levels of 7 analytes (CXCL8, CCL3, CCL4, GM-CSF, IL-6, IL-10 and TNF-α).  The inflammatory responses induced by both stimulations was supressed by dexamethasone for the majority of analytes. Conclusions: These data provide proof of concept that this ex vivo human lung explant model is responsive to inflammatory signals and could be used to investigate the anti-inflammatory effects of existing and novel compounds.  In addition this model could be used to help define the mechanisms and pathways involved in development of inflammatory airway disease. Abbreviations: COPD: Chronic Obstructive Pulmonary Disease; ICS: inhaled corticosteroids; LPS: lipopolysaccharide; IL-1β: interleukin-1 beta; PSF: penicillin, streptomycin and fungizonehttps://f1000research.com/articles/6-460/v1Airway/Respiratory PhysiologyCOPD & Allied DisordersDrug Discovery & Design
collection DOAJ
language English
format Article
sources DOAJ
author Tracy L Rimington
Emily Hodge
Charlotte K Billington
Sangita Bhaker
Binaya K C
Iain Kilty
Scott Jelinsky
Ian P Hall
Ian Sayers
spellingShingle Tracy L Rimington
Emily Hodge
Charlotte K Billington
Sangita Bhaker
Binaya K C
Iain Kilty
Scott Jelinsky
Ian P Hall
Ian Sayers
Defining the inflammatory signature of human lung explant tissue in the presence and absence of glucocorticoid [version 1; referees: 2 approved]
F1000Research
Airway/Respiratory Physiology
COPD & Allied Disorders
Drug Discovery & Design
author_facet Tracy L Rimington
Emily Hodge
Charlotte K Billington
Sangita Bhaker
Binaya K C
Iain Kilty
Scott Jelinsky
Ian P Hall
Ian Sayers
author_sort Tracy L Rimington
title Defining the inflammatory signature of human lung explant tissue in the presence and absence of glucocorticoid [version 1; referees: 2 approved]
title_short Defining the inflammatory signature of human lung explant tissue in the presence and absence of glucocorticoid [version 1; referees: 2 approved]
title_full Defining the inflammatory signature of human lung explant tissue in the presence and absence of glucocorticoid [version 1; referees: 2 approved]
title_fullStr Defining the inflammatory signature of human lung explant tissue in the presence and absence of glucocorticoid [version 1; referees: 2 approved]
title_full_unstemmed Defining the inflammatory signature of human lung explant tissue in the presence and absence of glucocorticoid [version 1; referees: 2 approved]
title_sort defining the inflammatory signature of human lung explant tissue in the presence and absence of glucocorticoid [version 1; referees: 2 approved]
publisher F1000 Research Ltd
series F1000Research
issn 2046-1402
publishDate 2017-04-01
description Background: Airway inflammation is a feature of many respiratory diseases and there is a need for newer, more effective anti-inflammatory compounds. The aim of this study was to develop an ex vivo human lung explant model which can be used to help study the mechanisms underlying inflammatory responses and which can provide a tool to aid drug discovery for inflammatory respiratory diseases such as asthma and COPD. Method: Parenchymal lung tissue from 6 individual donors was dissected and cultured with two pro-inflammatory stimuli, lipopolysaccharide (LPS) (1 µg/ml) and interleukin-1 beta (IL-1β) (10 ng/ml) in the presence or absence of dexamethasone (1 µM).  Inflammatory responses were assessed using Luminex analysis of tissue culture supernatants to measure levels of 21 chemokines, growth factors and cytokines. Results: A robust and reproducible inflammatory signal was detected across all donors for 12 of the analytes measured following LPS stimulation with a modest fold increase (<2-fold) in levels of CCL22, IL-4, and IL-2; increases of 2-4-fold in levels of CXCL8, VEGF and IL-6 and increases >4-fold in CCL3, CCL4, GM-CSF, IL-10, TNF-α and IL-1β.  The inflammatory signal induced by IL-1β stimulation was less than that observed with LPS but resulted in elevated levels of 7 analytes (CXCL8, CCL3, CCL4, GM-CSF, IL-6, IL-10 and TNF-α).  The inflammatory responses induced by both stimulations was supressed by dexamethasone for the majority of analytes. Conclusions: These data provide proof of concept that this ex vivo human lung explant model is responsive to inflammatory signals and could be used to investigate the anti-inflammatory effects of existing and novel compounds.  In addition this model could be used to help define the mechanisms and pathways involved in development of inflammatory airway disease. Abbreviations: COPD: Chronic Obstructive Pulmonary Disease; ICS: inhaled corticosteroids; LPS: lipopolysaccharide; IL-1β: interleukin-1 beta; PSF: penicillin, streptomycin and fungizone
topic Airway/Respiratory Physiology
COPD & Allied Disorders
Drug Discovery & Design
url https://f1000research.com/articles/6-460/v1
work_keys_str_mv AT tracylrimington definingtheinflammatorysignatureofhumanlungexplanttissueinthepresenceandabsenceofglucocorticoidversion1referees2approved
AT emilyhodge definingtheinflammatorysignatureofhumanlungexplanttissueinthepresenceandabsenceofglucocorticoidversion1referees2approved
AT charlottekbillington definingtheinflammatorysignatureofhumanlungexplanttissueinthepresenceandabsenceofglucocorticoidversion1referees2approved
AT sangitabhaker definingtheinflammatorysignatureofhumanlungexplanttissueinthepresenceandabsenceofglucocorticoidversion1referees2approved
AT binayakc definingtheinflammatorysignatureofhumanlungexplanttissueinthepresenceandabsenceofglucocorticoidversion1referees2approved
AT iainkilty definingtheinflammatorysignatureofhumanlungexplanttissueinthepresenceandabsenceofglucocorticoidversion1referees2approved
AT scottjelinsky definingtheinflammatorysignatureofhumanlungexplanttissueinthepresenceandabsenceofglucocorticoidversion1referees2approved
AT ianphall definingtheinflammatorysignatureofhumanlungexplanttissueinthepresenceandabsenceofglucocorticoidversion1referees2approved
AT iansayers definingtheinflammatorysignatureofhumanlungexplanttissueinthepresenceandabsenceofglucocorticoidversion1referees2approved
_version_ 1724657354051420160